Supplementary Figure 5 from The HSP90 Inhibitor Ganetespib Synergizes with the MET Kinase Inhibitor Crizotinib in both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models
Year: 2023
Type: supplementary-materials
Abstract: PDF file - 75K, A dose range study of single agent crizotinib and ganetespib in wtMET-driven or mutant MET-driven tumor xenografts.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361819824